Best Oestrogen Blocker for Man Boobs: UK Guide

The best oestrogen blocker for man boobs depends on the underlying cause, the duration of the condition, and whether true gynaecomastia or simple fatty tissue is involved. Gynaecomastia, the medical term for enlarged glandular breast tissue in men, is driven by a relative excess of oestrogen activity over testosterone in breast tissue. Selective oestrogen receptor modulators (SERMs) such as tamoxifen and raloxifene are the most evidence-backed pharmacological options, but both are prescription-only, used off-label, and require specialist oversight. This article explains what causes man boobs, which treatments are available in the UK, and when to seek medical advice.

What causes man boobs and what role does oestrogen play?

Man boobs (gynaecomastia) are caused by a hormonal imbalance where oestrogen activity is relatively higher than testosterone in breast tissue, stimulating glandular growth. Common triggers include puberty, ageing, certain medicines, recreational drugs, and underlying conditions such as hypogonadism or liver disease.

Gynaecomastia, the medical term for enlarged breast tissue in men, is caused by an imbalance between oestrogen and testosterone, where oestrogen activity is relatively higher than androgen activity in breast tissue.^[1] All men produce small amounts of oestrogen naturally, but when this rises relative to testosterone, glandular breast tissue can proliferate, producing a firm, sometimes tender swelling beneath the nipple. This is distinct from pseudogynaecomastia, which is fatty tissue accumulation without glandular growth and is not driven by hormonal imbalance in the same way. Pseudogynaecomastia is managed primarily through weight loss and lifestyle measures rather than hormonal treatment.

Several factors can tip this hormonal balance. Common causes include:

• Puberty, when temporary hormonal fluctuations are normal and usually resolve within one to two years^[1]

• Older age, as testosterone levels naturally decline

• Medicines, including anabolic steroids, spironolactone, some antipsychotics, certain antifungals, cimetidine, and 5-alpha-reductase inhibitors.^[10][11] Proton pump inhibitors have been reported in association with gynaecomastia in some case reports, though this is not consistently recognised in standard UK guidance and the evidence is limited^[12][13]

• Recreational drugs, including cannabis and alcohol

• Underlying conditions such as hypogonadism, hyperthyroidism, liver disease, kidney failure, or testicular tumours and other tumours that secrete human chorionic gonadotrophin (hCG), which can raise oestrogen levels

• Obesity, which increases peripheral conversion of androgens to oestrogens via the enzyme aromatase

It is important to distinguish true gynaecomastia from breast cancer, which, although uncommon in men, can present similarly. A firm, eccentric, or rapidly growing lump, skin changes, nipple discharge, or lymph node swelling should always be assessed promptly by a clinician. In most cases of gynaecomastia, identifying and addressing the underlying cause is the first and most important step, as this alone may allow the tissue to regress, particularly if the condition is recent in onset.

What treatments are available for gynaecomastia in the UK?

Treatment depends on the cause and duration; addressing the underlying trigger is the first step, and SERMs such as tamoxifen or raloxifene may be prescribed off-label by a specialist. Surgery is available for longstanding cases but is subject to NHS commissioning criteria that vary by Integrated Care Board.

Treatment for gynaecomastia in the UK depends on the underlying cause, the duration of the condition, and the degree of distress it causes. Addressing any identifiable trigger, such as stopping a causative medicine or treating an underlying hormonal disorder, is the recommended first step and may be sufficient, particularly when the condition has been present for less than one year, before fibrous tissue has had time to develop.

Where a pharmacological approach is considered, this is typically managed by a specialist rather than initiated in primary care. Medicines used in this context include:

• Tamoxifen, a selective oestrogen receptor modulator (SERM) that blocks oestrogen receptors in breast tissue

• Raloxifene, another SERM sometimes used off-label in this setting

• Aromatase inhibitors such as anastrozole, which reduce the conversion of androgens to oestrogens

None of these medicines currently holds a UK marketing authorisation specifically for gynaecomastia, meaning their use in this context is off-label. Clinical evidence, including data summarised in the Endocrine Society Clinical Practice Guideline on gynaecomastia, suggests that SERMs have a stronger evidence base than aromatase inhibitors for this indication.^[1] Prescribing decisions rest with the specialist, who will weigh potential benefits against risks on an individual basis. NICE does not have a specific technology appraisal for pharmacological treatment of gynaecomastia; NICE CKS provides primary care guidance on assessment and referral.

For longstanding gynaecomastia where fibrous tissue has formed, or where medical treatment has not produced adequate improvement, surgical options including subcutaneous mastectomy or liposuction may be considered. In the NHS, surgery for gynaecomastia is generally only commissioned where there is significant psychological impact and other criteria are met, and eligibility varies by Integrated Care Board (ICB). Private surgical options are also available. Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online consultations, with prescriber review and pharmacist support, though gynaecomastia typically requires specialist assessment rather than an online consultation alone.

Do oestrogen blockers actually work for reducing breast tissue in men?

SERMs such as tamoxifen and raloxifene can reduce breast tissue volume and tenderness, but only when used in the early, active phase before fibrosis develops. Aromatase inhibitors are less well evidenced for this indication, and self-medicating with unregulated supplements is not clinically supported.

Oestrogen blockers, specifically SERMs such as tamoxifen and raloxifene, can reduce breast tissue volume and associated tenderness in men with gynaecomastia, but their effectiveness depends significantly on how long the condition has been present. Clinical evidence, including small randomised trials and observational studies, suggests that SERMs are more effective when used in the early, active phase of gynaecomastia, typically within the first year, before the glandular tissue has been replaced by fibrous, non-responsive tissue.^[2][1] Once fibrosis has occurred, pharmacological treatment is unlikely to produce meaningful regression.

Tamoxifen works by competitively binding to oestrogen receptors in breast tissue, blocking the proliferative effect of oestrogen without reducing circulating oestrogen levels.^[5] Raloxifene acts similarly. Aromatase inhibitors take a different approach, reducing the amount of oestrogen produced by blocking the enzyme that converts androgens to oestrogens; however, evidence for their use in gynaecomastia is generally considered weaker than for SERMs, as reflected in international endocrine guidelines.

Potential adverse effects of these medicines are relevant to the prescribing decision:

• Tamoxifen: hot flushes, mood changes, and an increased risk of thromboembolic events. The UK Summary of Product Characteristics for tamoxifen notes an increased risk of venous thromboembolism; prescribers will assess individual risk factors accordingly^[5][6]

• Raloxifene: similarly carries an increased thromboembolic risk, and musculoskeletal symptoms^[3][4]

• Aromatase inhibitors: joint pain, reduced bone mineral density with prolonged use, and fatigue

Because these medicines are used off-label for gynaecomastia, treatment should only be initiated and monitored by a clinician with relevant expertise, such as an endocrinologist or specialist surgeon. Self-medicating with over-the-counter supplements marketed as "oestrogen blockers" is not supported by clinical evidence and carries its own safety risks.

Should I see my GP or a specialist about gynaecomastia?

Most men should start with their GP, who can examine the tissue, arrange blood tests, and review medicines before referring to an endocrinologist or surgeon if needed. An urgent two-week-wait referral is warranted if breast cancer cannot be excluded clinically, in line with NICE guidance NG12.

Most men with gynaecomastia should start by seeing their GP, who can take a history, examine the breast tissue, and arrange initial investigations to identify any underlying cause. Relevant investigations may include blood tests to assess testosterone, luteinising hormone (LH), follicle-stimulating hormone (FSH), oestradiol, prolactin, thyroid function, liver function, and renal function.^[1] Where a testicular tumour or other hCG-secreting malignancy is suspected, the GP should also arrange testicular examination and consider serum beta-hCG and alpha-fetoprotein (AFP) testing, with testicular ultrasound where indicated.^[1] The GP can also review current medicines and recreational drug use, which are among the most common reversible causes.

Referral to a specialist is appropriate in a number of circumstances, including:

• Uncertainty about the diagnosis, particularly if breast cancer cannot be excluded clinically

• Rapid or asymmetrical growth, nipple discharge, or skin changes

• Persistent gynaecomastia lasting more than one year despite addressing identifiable causes

• Significant psychological distress affecting quality of life

• Consideration of pharmacological or surgical treatment, which requires specialist input

Under NICE guidance on suspected cancer (NG12), an urgent two-week-wait referral for suspected breast cancer should be considered for men with a unilateral, firm, subareolar breast mass with or without skin tethering or nipple distortion, or for men aged 50 and over with unilateral nipple changes such as discharge, retraction, or other concerning features.^[8][9] If you notice a new, rapidly growing, or painful lump in the breast area, contact your GP promptly rather than waiting. If you experience any symptoms that concern you acutely, contact NHS 111 for urgent advice.

Depending on the clinical picture, specialist referral may be to an endocrinologist, a breast surgeon, or a plastic surgeon. In the NHS, waiting times vary by ICB and local commissioning arrangements.

Suspected adverse drug reactions to any medicine involved in your care can be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk. Self-treating with unregulated supplements or medicines purchased online without a prescription is not recommended and may carry significant health risks.

Scientific References

1. EAA clinical practice guidelines – gynecomastia evaluation and management.
2. Beneficial effects of raloxifene and tamoxifen in the treatment of pubertal gynecomastia.
3. Raloxifene Teva 60 mg film-coated tablets – EPAR Product Information.
4. Raloxifene hydrochloride – BNF.
5. Tamoxifen 20 mg Film-Coated Tablets – Summary of Product Characteristics.
6. Tamoxifen and risk of idiopathic venous thromboembolism.
7. MHRA Safety Roundup: November 2025.
8. Suspected cancer: recognition and referral (NG12).
9. Suspected cancer: recognition and referral – full guideline PDF (NG12).
10. Drug-induced gynecomastia: a systematic review and meta-analysis of randomised clinical trials.
11. Adverse effects associated with long-term administration of azole antifungal agents.
12. Risk of gynecomastia with users of proton pump inhibitors.
13. Gynaecomastia associated with proton pump inhibitors.
14. Aromatase inhibitors plus weight loss improves the hormonal profile of obese hypogonadal men without causing major side effects.
15. The effect of aromatase on the reproductive function of obese males.
16. MHRA authorises anastrozole to prevent breast cancer in post-menopausal women.
17. Drug treatment to reduce the risk of breast cancer (CG164).
18. About anastrozole.

Frequently Asked Questions